主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KROS
#2417
Keros Therapeutics, Inc. Common Stock
14.190
0
-3.14%
版块:
基础:
利润货币:
日范围
年范围
日变化
-3.14%
每月变动
-21.86%
6个月变化
-6.03%
年变化
-6.03%
前一天收盘价
14.650
0
Open
14.190
0
Bid
Ask
Low
14.190
0
High
14.190
0
交易量
60
市场
股票
医疗保健
KROS
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
23.27 M
24 M
28.54 M
35.98 M
40.56 M
—
Valuation ratios
Enterprise value
1.38 B
1.17 B
1.03 B
1.22 B
82.2 M
-583.97 M
Price to earnings ratio
—
-23.22
-11.08
-8.29
-3.17
-11.18
Price to sales ratio
—
67.92
—
8 410.96
166.94
173.86
Price to cash flow ratio
—
21.97
16.56
10.2
3.68
11.18
Price to book ratio
—
5.61
4.18
3.82
1.04
1.65
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.23
0.34
0.41
0.3
0.31
Return on equity %
0.17
0.24
0.38
0.46
0.33
0.34
Return on invested capital %
8 687.99
2 651.3
2 569.73
3 007.41
3 104.01
2 815.51
Gross margin %
—
100
—
100
100
400
Operating margin %
—
280.46
—
112.54 K
5 938.96
2 150.7
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
292.26
—
101.32 K
5 277.55
1 803.81
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
37.27
21.23
17.27
14.25
21.45
91.71
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.08
0
0
0.01
0.35
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
2.66
2.78
4.23
4.3
4.51
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
9.86
11.05
11.25
14.96
66.59
Net current asset value per share
—
10.78
11.32
11.79
15.73
70
Tangible book value per share
—
10.42
10.99
11.28
15.27
67.76
Working capital per share
—
10.27
10.67
10.97
15
66.85
Book value per share
—
10.42
10.99
11.28
15.27
67.76
新闻
Keros Therapeutics任命前Lyell首席财务官加入董事会
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Is KROS' KER-065 the Next Breakthrough in DMD Space?
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?